

A modeling study of the opioid epidemic for vulnerable communities in Knoxville, Tennessee

Kimberlyn Eversman

keversma@vols.utk.edu

University of Tennessee at Knoxville

Adam Spannaus

Oak Ridge National Laboratory

Ryan Campbell

University of Tennessee at Knoxville

Leigh B. Percy

University of Pittsburgh

Jodie Trafton

Veterans Health Administration

Anuj Kapadia

Oak Ridge National Laboratory

W. Christopher Strickland

University of Tennessee at Knoxville

Research Article

Keywords: Opioid use disorder, Substance use disorder, Opioid epidemic, Public health, Compartment model, Epidemiological model

Posted Date: December 4th, 2025

DOI: <https://doi.org/10.21203/rs.3.rs-8148367/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

1 A modeling study of the opioid epidemic for
2 vulnerable communities in Knoxville, Tennessee.

3 Kimberlyn Eversman^{1*}, Adam Spannaus³, Ryan Campbell¹,
4 Leigh B. Pearcy⁴, Jodie Trafton⁵, Anuj Kapadia³,
5 W. Christopher Strickland^{1,2*}

6 ¹Department of Mathematics, University of Tennessee, Knoxville,
7 Knoxville, 37916, TN, USA.

8 ²Department of Ecology and Evolutionary Biology, University of
9 Tennessee, Knoxville, Knoxville, 37916, TN, USA.

10 ³Computational Sciences and Engineering Division, Oak Ridge National
11 Laboratory, Oak Ridge, 37830, TN, USA.

12 ⁴Department of Psychiatry, University of Pittsburgh, Pittsburgh,
13 15213, PA, USA.

14 ⁵Office of Mental Health, Veterans Health Administration, Palo Alto,
15 94025, CA, USA.

16 *Corresponding author(s). E-mail(s): keversma@vols.utk.edu;
17 cstric12@utk.edu;

18 Contributing authors: spannausat@ornl.gov; rcampb24@vols.utk.edu;
19 lbp35@pitt.edu; jodie.trafton@va.gov; kapadiaaj@ornl.gov;

20 **Abstract**

21 **Background:** Over the past three decades, the opioid epidemic has emerged as
22 one of the most pressing public health crises in the United States, disproportion-
23 ately affecting vulnerable communities and minority populations. Mathematical
24 modeling, widely applied in the study of infectious diseases, offers a rigorous
25 framework to investigate the dynamics of opioid use disorder.

26 **Methods:** We present a compartmental model to examine two primary risk fac-
27 tors for opioid misuse: opioid availability and access to preventive resources. The
28 framework consists of two interacting systems of equations, one representing the
29 general population and the other a subset community of interest. The general

population model was calibrated using 2016-2019 data from the Knoxville, Tennessee Metropolitan Statistical Area, a region heavily impacted by the epidemic. Sensitivity analyses were conducted to quantify the influence of model inputs on outcomes.

Results: Embedded within a data-calibrated general population, simulations of hypothetical communities were conducted under varying levels of treatment accessibility, recovery retention, and fatal overdose rates. We found that variations in recovery retention and fatal overdose risk exerted the strongest influence on total overdoses. Notably, increasing treatment access alone—without simultaneously addressing other factors such as relapse reduction—was associated with higher overdose rates, as individuals almost exclusively relapsed using fentanyl or heroin, rather than prescription opioids, all of which carry elevated fatal overdose risk.

Conclusions: For Knoxville during 2016–2019, increasing resources aimed at preventing the initial development of opioid use disorder would likely have had minimal effect on the overall prevalence of opioid use disorder. Our analysis highlights the importance of model scope, as a related study, which was fitted to a broader geographic area and a longer time span, produced findings that differed from ours. While our conclusions are specific to this location and period, the modeling framework we created is readily adaptable to other regions and populations, provided appropriate data is available, and offers a valuable tool for studying vulnerable groups.

Keywords: Opioid use disorder, Substance use disorder, Opioid epidemic, Public health, Compartment model, Epidemiological model

1 Background

Over the past three decades, the opioid epidemic has become one of the most significant public health crises in the United States. The dramatic increases in the misuse of both prescription and non-prescription opioids have led to a staggering rise in deaths from opioid-related overdoses (ODs), with the number of people who died from a drug OD in 2022 being approximately six times larger than in 1999, with almost 76% of these deaths involving an opioid [1].

The opioid epidemic began in the 1990s, when heightened concerns about under-treated pain led physicians to increase opioid prescribing dramatically [2, 3]. The resulting surge fueled a rise in prescription opioid use disorder (POUD) [4]. Unlike many other illicit substances, misused prescription opioids were most often obtained

65 from leftover pills shared by friends or family, rather than directly from prescriptions
66 or dealers [5]. Between 1999 and 2017, fatal ODs involving prescription opioids rose
67 sharply from 3,442 to 17,029 [6], defining the first wave of ODs of the crisis.

68 Efforts to curb prescription opioid misuse—through updated prescribing guidelines
69 [7, 8] and the development of abuse-deterrent formulations [9, 10]—were accompanied
70 by a surge in heroin use, fueled by its greater availability and lower cost. Many who
71 turned to heroin had first misused prescription opioids [11]. Between 2010 and 2012,
72 heroin OD deaths more than doubled across 28 states [12], marking the beginning of
73 the crisis’s second wave.

74 The third, and still ongoing, wave of the crisis began in 2013 with the emergence
75 of illicit fentanyl, a synthetic opioid 50 to 100 times more potent than morphine [13].
76 Frequently mixed into other drugs without the user’s knowledge, fentanyl has fueled
77 a steep rise in fatal ODs. By 2022, the death rate from synthetic opioids was nearly
78 25 times higher than in 2010 [14].

79 The opioid epidemic has not affected all populations equally, however. Many com-
80 munities and minority groups have been disproportionately impacted, with certain
81 populations facing heightened vulnerability to developing opioid use disorder (OUD)
82 [15], significant barriers to accessing and receiving treatment [16], and increased risk
83 of fatal OD [17, 18]. For example, Black individuals are less likely than their white
84 peers to be prescribed medications for OUD [19], and people living in poverty or with-
85 out health insurance face a substantially greater risk of dying from an opioid OD [20].
86 However, some groups have access to specialized resources that can help mitigate these
87 risks. For instance, although military personnel may be at elevated risk for develop-
88 ing an OUD, they benefit from targeted programs and support services that are often
89 unavailable to the general public [21, 22].

90 Geographic disparities are also pronounced. The Appalachian Region, for example,
91 has experienced opioid OD rates more than twice the national average [23]. A historical

reliance on injury-prone industries made this region an early target for the aggressive marketing of prescription opioids [24].

While these examples highlight differences in how the epidemic affects specific populations—particularly minorities and other vulnerable groups—the surrounding population still plays a critical role in shaping outcomes. Previous modeling studies have examined the opioid epidemic from various perspectives [25–48], but, to our knowledge, none have specifically investigated how a vulnerable subcommunity may be affected by the broader population surrounding it. More details on previous modeling studies can be found in the online supplementary material.

To address this gap, we have developed a model examining two major risk factors for opioid misuse—availability of opioids (including prescription opioids, fentanyl, and heroin) and access to essential preventative resources (such as therapy, physical rehabilitation, and medical care)—within a community of interest. Our approach uses two interacting systems of ordinary differential equations (ODEs): one representing the general population and the other representing a subset community of interest. Our analysis focuses on the Knoxville Metropolitan Statistical Area (MSA) in Tennessee, U.S., located within the Appalachian region, for the period 2016–2019. This model is easily adaptable to other locations and time periods, provided the necessary data are available.

The time span for our study is the years 2016 to 2019 for two reasons: (1) between 2015 and 2016, OD deaths from synthetic opioids (such as fentanyl) surpassed those from heroin and prescription opioids nationally, a trend that has continued since [1], and (2) we conclude in 2019 due to disruptions caused by the COVID-19 pandemic [49]. More information on these disruptions can be found in the supplementary material. After calibrating the model to Knoxville MSA data, we explore several hypothetical communities to assess how they would be affected by the opioid epidemic under similar conditions. We propose a simple yet robust modeling framework that captures how

different communities are uniquely impacted over time, while remaining adaptable for application to other locations and communities.

2 Methods

2.1 Model

The terminology related to OUD can be ambiguous—often used interchangeably with terms such as abuse, addiction, dependence, or misuse. For clarity, we adopt the definition of substance use disorder as outlined in the DSM-5 [50]. In this context, we categorize opioid addiction as a specific manifestation of OUD; a more detailed description is available in the supplementary material.

At its root, OUD is a disease; thus, we use a compartment modeling method popular in disease epidemiology to study its dynamics. We developed two interacting, deterministic, compartmental models of OUD among individuals aged 12 and older for the Knoxville MSA: one representing the general population and another for a specific community of interest, which is a subset of the general population. The compartments represent the proportions of the general population and the proportions of the community for the respective models. Table 1 provides a detailed description of each compartment.

Figure 1 and Figure 2 depict the compartmental structures of the general population and community models, respectively. By having these two interacting models, we can examine the effects of the availability of opioids in the general population surrounding the community. Additionally, we stratify the susceptible community into susceptibles without and with chronic pain, denoted S_C and S_H , to determine the effects of access to preventative resources, such as physical therapy. Full model details and assumptions are available in the supplementary material.

In the community model, susceptible individuals without chronic pain (S_C) may develop chronic pain, moving them to the susceptible individuals with chronic pain

Table 1 Description of compartments in the general population model and community model

State	Indicator	Description
General population susceptibles	S_G	Proportion of the general population who are not using prescribed opioids, fentanyl, or heroin.
Community susceptibles without chronic pain	S_C	Proportion of the community who are not using prescribed opioids, fentanyl, or heroin and who do not have chronic pain.
Community susceptibles with chronic pain	S_H	Proportion of the community who are not using prescribed opioids, fentanyl, or heroin and who have chronic pain.
General population/community prescription opioid users	$P_{G/C}$	Proportion of the general population/community who are prescribed opioids by a health care provider and take them in a manner not constituting an opioid use disorder (some misuse is possible, as long as it is in a manner such that potential for immediate harm is negligible).
General population/community prescription opioid use disorders	$A_{G/C}$	Proportion of the general population/community who have a POUD but are not using fentanyl or heroin. They may be actively in treatment for opioid use disorder and are still considered in this class for one month after being discharged from treatment, regardless of current use.
General population/community fentanyl or heroin use disorders	$F_{G/C}$	Proportion of the general population/community who have a fentanyl or heroin use disorder (FHUD) or are actively in treatment for opioid use disorder, including fentanyl/heroin. Individuals remain in this class for at least one month after being discharged from treatment, regardless of current use.
General population/community stably recovered individuals	$R_{G/C}$	Proportion of the general population/community who have completed treatment for OUD and do not relapse within one month after treatment is over. In cases where treatment is not a well-defined, discrete event (e.g., ongoing counseling, group support, solo attempts at recovery), one month without relapse alone characterizes inclusion in $R_{G/C}$ versus $A_{G/C}$ or $F_{G/C}$.

145 class (S_H). Once in this class, individuals may move back to the susceptible individuals
 146 without chronic pain (S_C), either through the route of being prescribed opioids or may
 147 move directly there. While this direct route could happen naturally over time, it is
 148 also subject to the availability of certain non-opioid resources, like physical therapy. In
 149 both models, all susceptible individuals may be prescribed opioids, though individuals
 150 with and without chronic pain are prescribed at differing rates.

151 Susceptibles and prescription opioid users may develop POUD through one of
152 three pathways: (1) progression from their own prescription use, (2) interactions with
153 individuals who have POUD (including illicit purchases), or (3) use of leftover or stolen
154 prescription opioids—modeled as interactions with individuals who have prescriptions.

155 Additionally, susceptibles, prescription opioid users, and individuals with POUD
156 can develop a fentanyl or heroin use disorder (FHUD) through interactions with people
157 who have FHUD.

158 Due to the challenges of OUD recovery and high relapse rates [51], individuals
159 with POUD or FHUD do not enter the stably recovered compartment until they
160 have completed treatment and remained relapse-free for one month. In cases where
161 treatment is not a well-defined, discrete event (e.g., ongoing counseling, group support,
162 solo attempts at recovery), one month without relapse alone characterizes inclusion
163 into the stably recovered compartment versus the POUD or FHUD compartments.
164 Individuals in the stably recovered compartment may relapse into either the POUD
165 or FHUD compartments.

166 All compartments include a natural mortality rate. Those in the POUD and FHUD
167 compartments have an additional mortality rate due to their increased chance of fatal
168 ODs.

169 Lastly, all of the model parameters are continuous values except for α_G , α_C , and
170 α_H , which are linear terms based on time such that $\alpha_X = \tilde{m}_X t + \tilde{b}_X$, where $X \in$
171 $\{G, C, H\}$.

172 2.2 Parameter Estimation

173 Using the weighted least squares method, we fit the general population model to
174 publicly available data for the Knoxville MSA covering the years 2016 to 2019. More
175 details on the data and the parameter estimation are available in the supplementary
176 material.




Fig. 1 Connection diagram of the general population model for the various compartments, where the arrows represent the direction of movement of individuals from one to the other

2.3 Sensitivity Analysis

To identify and quantify the influence of model inputs — parameters and initial conditions — on model outputs, defined as the class values at the final time point, we performed a Sobol sensitivity analysis (SA). The Sobol method partitions the model's output variance into fractions attributed to the model inputs or combinations of interacting inputs; these fractions serve as a measure of sensitivity [52]. A detailed description of our use of the Sobol SA method, along with the model input ranges used, is available in the supplementary material.

3 Results

3.1 Parameter Estimation

Table 2 presents the estimated parameter values for the general population model. Figure 3 compares the general population model simulation outputs to observed data, including yearly and quarterly prescription opioid users without a POUD, yearly POUD and FHUD prevalence, and yearly fatal OD counts for both POUD and FHUD.




Fig. 2 Connection diagram of the community model for the various compartments, where the arrows represent the direction of movement of individuals from one to the other

3.2 Sensitivity Analysis

The Sobol SA total-order index results, which describe the proportion of the total model output variance that remains when uncertainty is removed from all other inputs except this input, can be seen in Figure 4. The length of the colored bars represents the contribution of that parameter to the variance of that population class at the final time; the longer the colored bars, the higher the effect of that parameter on that class.

The Sobol SA first-order index results are available in the supplementary material. The first-order index and the total-order index results were found to be very similar, suggesting there are no significant interactions between the input parameters.

3.3 Community Scenarios

We now investigate how different hypothetical communities might fare during the study period, given their interactions with the surrounding general population, which is rooted in real-world data. To determine the hypothetical communities, we focus on




Fig. 3 General population model simulation results fit to data, which includes yearly prescription opioid data, quarterly prescription opioid data, yearly POUD data, yearly FHUD data, yearly POUD fatal OD data, and yearly FHUD fatal OD data.

the parameters identified through the Sobol sensitivity analysis as having the most significant impact on the community OUD classes (A_C and F_C) and stably recovered class (R_C) at the start of 2020, as changes in R_C could also influence fatal ODs. More precisely, we examine how communities fare under differing conditions of treatment accessibility (ζ and ν), recovery retention (σ), and fatal OD risk (μ_A and μ_F).

To establish a baseline for the community-specific parameters, we select parameter values and initial conditions that closely reproduce the overall output of the general population model. Additional details on the baseline parameterization are provided in the supplementary materials.

Our initial modeling objective was to maintain simplicity—minimizing the number of parameters—to ensure it is adaptable to various contexts. However, since the parameters we are interested in varying (ζ , ν , σ , μ_A , and μ_F) are shared between the general population and community models, we distinguish them to explore community-specific effects. For instance, when assessing the influence of varying σ , we replace it in the

Table 2 Estimated parameter values for the general population model

Input	Estimated Value	Units
$\tilde{m}_G$	-0.0288	$\frac{1}{\text{year}}$
$\tilde{b}_G$	0.332	$\frac{1}{\text{year}}$
β_{GA}	0.001	$\frac{1}{\text{year}}$
β_{GP}	0.0001	$\frac{1}{\text{year}}$
θ_{SG}	0.00111	$\frac{1}{\text{year}}$
θ_P	0.0101	$\frac{1}{\text{year}}$
θ_A	48.9	$\frac{1}{\text{year}}$
ε_G	7.0	$\frac{1}{\text{year}}$
γ	1.16×10^{-5}	$\frac{1}{\text{year}}$
ζ	0.0536	$\frac{1}{\text{year}}$
ν	0.00319	$\frac{1}{\text{year}}$
σ	0.97	$\frac{1}{\text{year}}$
λ_A	0.00633	$\frac{1}{\text{year}}$
λ_F	1.0	$\frac{1}{\text{year}}$
μ_A	0.0471	$\frac{1}{\text{year}}$
μ_F	0.471	$\frac{1}{\text{year}}$
P_{G_0}	0.0432	dimensionless
A_{G_0}	0.00246	dimensionless
F_{G_0}	0.000339	dimensionless
R_{G_0}	0.000508	dimensionless

community model with σ_C to allow independent variation of the community-specific parameter, σ_C , while not affecting the general population model.

For each hypothetical community scenario, we vary the parameter of interest by $\pm 25\%$ and $\pm 50\%$ from its baseline value and rerun the model over our study period. We then evaluate how these changes affect the community OUD classes (A_C and F_C) and stably recovered class (R_C) at the final time point, as well as the resulting impact on fatal ODs.

3.3.1 Accessibility to Treatment

We aim to investigate how changes in ζ , the rate at which individuals with POUD stably recover, affect the community. To isolate this effect, we introduce a new parameter, ζ_C , which replaces ζ in the community ODEs. This modification allows us to assess the impact of changes in recovery rates specifically within the community context. An




Fig. 4 Sobol sensitivity results for the size of each class at the beginning of 2020 run over four years with 2,752,512 samples for the total-order indices.

increase in ζ_C may represent expanded access to treatment for individuals with POUD in the community, while a decrease could reflect diminished treatment availability.

Recognizing that shifts in community treatment access for POUD may also influence individuals with FHUD, we introduce a corresponding parameter, ν_C , representing the stable recovery rate for individuals with FHUD in the community. This parameter replaces ν in the community ODEs to reflect analogous changes in access to care.

We vary both ζ_C and ν_C by $\pm 25\%$ and $\pm 50\%$ from the baseline values of ζ and ν , respectively. The results of these simulations are presented in Table 3.

Interestingly, increasing these recovery rates (ζ_C and ν_C) leads to a decrease in A_C —as one might expect—but leads to an increase in F_C and an increase in fatal ODs from the baseline. This is because, in the model, there is minimal relapse into the POUD class, and the majority of relapses go into the FHUD class because of the estimated values of λ_A and λ_F . Thus, increasing R_C , which would be done by

Table 3 Effect on size of the A_C , F_C , R_C classes at the start of 2020 from altering ζ_C and ν_C by $\pm 25\%$ and $\pm 50\%$ from the baseline value, as well as the effect on the total number of fatal ODs between 2016 and 2019.

Value of ζ_C	Value of ν_C	Change in ζ_C, ν_C	Change in A_C	Change in F_C	Change in R_C	Change in Total ODs
0.026800	0.001596	-50.0%	$+11.2\%$	-16.9%	-41.4%	-4.3%
0.040200	0.002394	-25.0%	$+5.46\%$	-8.24%	-19.9%	-2.11%
0.053600	0.003192	0.0%	—	—	—	—
0.067000	0.003989	$+25.0\%$	-5.17%	$+7.81\%$	$+18.3\%$	$+2.05\%$
0.080400	0.004787	$+50.0\%$	-10.1%	$+15.2\%$	$+35.2\%$	$+4.03\%$

increasing the recovery rates (ζ_C and ν_C), leads to more people relapsing into F_C rather than A_C , answering the question as to why F_C increases.

We also note that increasing accessibility to treatment (increasing ζ_C and ν_C) alone leads to an increase in fatal ODs for the community. This can also be explained by the high relapse rate into the FOUOD class, which has a much higher fatal OD rate than the POUD class (an order of magnitude higher). Thus, the fatal ODs coming from the increased F_C outweigh the decrease in fatal ODs coming from A_C .

3.3.2 Retention of Stably Recovered Individuals

We now examine how changes in σ , the relapse rate of stably recovered individuals, influence community dynamics. Specifically, we replace σ in the community ODE with σ_C , varying it by $\pm 25\%$ and $\pm 50\%$ from its baseline value, and simulate the resulting scenarios. A decrease in σ_C corresponds to a lower relapse rate—indicating a higher likelihood of individuals remaining stably recovered—which may reflect enhanced post-treatment monitoring or improved access to medications for opioid use disorder (MOUD). MOUD have been shown to support recovery more effectively than counseling or psychosocial support alone [53]. The results are presented in Table 4.

We observe that varying σ_C had a minimal effect on A_C and F_C at the final time, but it significantly impacted R_C at the final time. This led to a significant change in the total number of ODs over the time period. A community with better retention in

recovery (reducing σ_C by 50%) had the potential to reduce its fatal ODs by nearly 10%, while a community with worse retention in recovery (increasing σ_C by 50%) had the potential to lose nearly 4% more to fatal ODs.

Table 4 Effect on size of the A_C , F_C , R_C classes at the start of 2020 from altering σ_C by $\pm 25\%$ and $\pm 50\%$ from the baseline value, as well as the effect on the total number of fatal ODs between 2016 and 2019.

Value of σ_C	Change in σ_C	Change in A_C	Change in F_C	Change in R_C	Change in Total ODs
0.485000	-50.0%	-0.0307%	-3.71%	+136.0%	-9.78%
0.727500	-25.0%	-0.00948%	+0.025%	+45.2%	-3.67%
0.970000	0.0%	—	—	—	—
1.212500	+25.0%	+0.00462%	-1.0%	-24.7%	+2.34%
1.455000	+50.0%	+0.00713%	-2.1%	-39.6%	+3.91%

3.3.3 Change in Fatal OD Rates

We aim to investigate how changes in the fatal OD death rates, μ_F and μ_A , impact the community. Given the interconnected nature of opioid use patterns, a change in the fatal OD rate among individuals with POUD in the community is likely to influence those with FHUD as well, and vice versa. Therefore, we examine the combined effects of varying these two parameters on the community. To isolate the effects within the community, we introduce new parameters, μ_{F_C} and μ_{A_C} , which replace μ_F and μ_A , respectively, in the community ODEs.

A reduction in μ_{F_C} and μ_{A_C} may represent increased availability of harm reduction resources in the community, such as Naloxone—a medication that rapidly reverses opioid ODs [54]—or fentanyl test strips, which help individuals detect the presence of fentanyl in other drugs such as heroin. Because fentanyl is extremely potent and frequently mixed into other illicit drugs in unknown quantities [55], access to testing strips can play a critical role in reducing the risk of fatal OD.

280 We vary μ_{F_C} and μ_{A_C} by $\pm 25\%$ and $\pm 50\%$ from the baseline values of μ_A and μ_F ,
 281 respectively. The resulting outcomes are presented in Table 5.

Table 5 Effect on size of the A_C , F_C , R_C classes at the start of 2020 from altering μ_{F_C} and μ_{A_C} by $\pm 25\%$ and $\pm 50\%$ from the baseline value, as well as the effect on the total number of fatal ODs between 2016 and 2019.

Value of μ_{F_C}	Value of μ_{A_C}	Change in μ_{F_C} , μ_{A_C}	Change in A_C	Change in F_C	Change in R_C	Change in Total ODs
0.235500	0.023550	-50.0%	+9.83%	+75.2%	+7.19%	-36.4%
0.353250	0.035325	-25.0%	+4.8%	+31.0%	+3.48%	-15.9%
0.471000	0.047100	0.0%	—	—	—	—
0.588750	0.058875	+25.0%	-4.58%	-22.1%	-3.27%	+12.8%
0.706500	0.070650	+50.0%	-8.95%	-38.1%	-6.38%	+23.4%

282 The changes in A_C , F_C , and R_C are not of particular interest to us in this commu-
 283 nity case because, as one would expect, if we increase/decrease the rate of fatal ODs,
 284 this leads to reductions/additions in the OUD classes and recovery classes. Here, we
 285 focus on the changes to the total fatal ODs.

286 We see that a community with more access to OD-reversing drugs like Naloxone or
 287 fentanyl test strips (decreasing μ_{F_C} and μ_{A_C} by 50%) had the potential to decrease its
 288 fatal ODs by approximately 36%, while a community with less access (decreasing μ_{F_C}
 289 and μ_{A_C} by 50%) had the potential to lose approximately 23% more to fatal ODs.

290 4 Discussion

291 4.1 Principal findings

292 Our analysis revealed that variations in fatal OD rates (μ_A and μ_F) and recovery
 293 retention rates (σ) in the hypothetical communities had the greatest impact on total
 294 fatal ODs during 2016–2019 in the Knoxville MSA. This suggests that, for this location
 295 and time period, the factors most likely to influence outcomes—either positively or

negatively—were access to and education on harm-reduction resources, such as Naloxone and fentanyl test strips, along with the availability of post-treatment monitoring and access to MOUD.

Additional insights gained through our model exploration included finding that relapse predominantly occurred into the FHUD classes rather than the POUD classes. The estimated value for λ_A was near zero, while λ_F was estimated at one (see Table 2). This implies that, regardless of the proportion of the community in the POUD or FHUD classes, individuals who relapse tend almost exclusively to re-enter the FHUD class. This result is consistent with the understanding that part of the draw to heroin and fentanyl over prescription opioids is their availability and lower cost [11]. Consequently, the relatively large relapse rate into the FHUD class, which carries a higher fatal OD risk than the POUD class, helps explain why expanding access to treatment alone (increasing ζ and ν) in the community without simultaneously addressing other factors, such as relapse reduction, could actually increase fatal ODs.

Further analysis indicated that the susceptible and prescribed classes function almost as a separate system from the OUD and stably recovered classes. Several key observations support this conclusion. First, the estimated parameter values for transitions from the susceptible and prescribed classes to the OUD and stably recovered classes were notably low. These parameters— β_{GA} , β_{GP} , γ , θ_P , and θ_{SG} —can be found in Table 2, and most of their estimated values were very close to the lower bounds of the ranges used for the least squares parameter estimation, despite the wide ranges used. Second, the Sobol SA revealed that these same parameters, along with their corresponding community counterparts (β_{CA} , β_{HA} , β_{CP} , β_{CP} , θ_{SC} , and θ_{SH}), did not significantly influence the sizes of the OUD or stably recovered classes at the start of 2020. Finally, parameters linked to transitions between susceptible and prescribed classes ($\tilde{m}_G$, $\tilde{b}_G$, ε_G , $\tilde{m}_C$, $\tilde{b}_C$, ε_C , $\tilde{m}_H$, $\tilde{b}_H$, ε_H , ρ_C , and ρ_H) also showed negligible effects on the OUD and stably recovered class sizes at the 2020, according to the SA.

323 Taken together, these results suggest that the development of OUD from personal pre-
324 scriptions or leftover prescriptions from others did not play a significant role in the
325 opioid epidemic during this time period. Granted, this does not suggest that prescrib-
326 ing regulations and the like during this time should have been rolled back, but rather
327 that the ones in place were likely functioning as intended.

328 As a result of the segregation between the susceptible and prescribed classes from
329 the OUD and stably recovered classes in the community, we see that the parameters
330 associated with access to essential preventative resources, ρ_C and ρ_H , had little effect
331 on the proportion of the community with an OUD. This is evident by the Sobol SA
332 results in Figure 4. This suggests that adding more resources to measures that reduce
333 the number of opioid prescriptions, like access to physical therapy, during this time
334 would not have a strong effect on preventing the development of OUD or preventing
335 OD deaths in the community.

336 4.2 Strengths and limitations of this study

337 To our knowledge, this is the first model to explicitly examine the impact of general
338 population dynamics on a specific community of interest. The model is also well-
339 suited to incorporate additional community-level data to refine parameter estimates
340 when such data are available. For example, communities such as veterans—where more
341 detailed data are often collected—present a valuable opportunity to enhance model
342 precision and tailor scenario analyses to specific groups.

343 All results presented here are specific to the dataset used in our model, i.e., the
344 Knoxville MSA data from 2016 to 2019. This likely explains some of the differences
345 between our findings and those of Phillips et al. (on which our model is based), who
346 analyzed Tennessee state-level data from 2013 to 2019 [46]. Because our dataset is a
347 geographic and temporal subset of theirs, these differences underscore the importance
348 of scope—both location and time—when interpreting model outcomes. Conclusions

drawn from our results should therefore not be assumed to apply directly to other regions or periods.

The modeling framework is flexible and can be adapted by fitting its parameters to data from other locations or time frames. Doing so could produce substantially different results and may reveal that certain structural elements—such as stratifying the susceptible community into those with and without chronic pain—are critical for understanding and controlling the opioid epidemic in a given context.

4.3 Future Research

With data from a specific real-world community, it would be possible to calibrate the community-level parameters in our model and examine in greater detail how the surrounding general population influences outcomes. Depending on the characteristics of the community, it may also be necessary to further stratify the model’s classes to refine recommendations. For example, if veterans were the community of interest, compartments could be divided based on the presence or absence of post-traumatic stress disorder (PTSD), since benzodiazepines—commonly prescribed for PTSD—can significantly increase OD risk when combined with opioids [56, 57]. Such refinements would require fitting additional parameters, essentially repeating the initial model for each subgroup. These extensions would not necessarily be more complex, highlighting the value of first establishing a clear understanding of the simpler base model.

As more data becomes available, the model could be extended beyond 2019 to capture the effects of the COVID-19 pandemic on the opioid epidemic. While OUD-specific data during the peak of the pandemic (years 2019 to 2020) does not exist for this area [49], existing records show that fatal opioid ODs in the Knoxville MSA were declining before 2020 but rose again in 2020 and 2021. This pattern suggests a pandemic-related impact, though the full scope may never be completely understood. Importantly, post-COVID data may not be directly comparable to pre-COVID

375 data, potentially necessitating the development of separate models for each period. If
376 community-specific data from the pandemic years is available, it could provide rare
377 and valuable insights into how OUD trends shifted during this time.

378 Ultimately, incorporating richer datasets will enable more accurate and tai-
379 lored management strategies—both at the community level and for individual
380 patients—leading to more precise, evidence-based recommendations for the continued
381 improvement in the management of OUD.

382 5 Abbreviations

383 ***FHUD***: fentanyl or heroin use disorder

384 ***MOUD***: medications for opioid use disorder

385 ***MSA***: Metropolitan Statistical Area

386 ***OD(s)***: overdose(s)

387 ***ODE(s)***: ordinary differential equation(s)

388 ***OUD***: opioid use disorder

389 ***POUD***: prescription opioid use disorder

390 ***SA***: sensitivity analysis

391 References

392 [1] Centers for Disease Control and Prevention. Centers for Disease Control and
393 Prevention, editor.: Understanding the Opioid Overdose Epidemic. Centers for
394 Disease Control and Prevention. Accessed 10/30/24. [https://www.cdc.gov/over-](https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html)
395 [dose-prevention/about/understanding-the-opioid-overdose-epidemic.html](https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html).

396 [2] West Virginia Department of Health and Human Resources. West Virginia
397 Department of Health and Human Resources, editor.: Prescription Drug Misuse
398 in West Virginia. West Virginia Department of Health and Human Resources.

- 399 Accessed 10/31/24, <https://dhhr.wv.gov/vip/Prescription-Drug/Pages/default.aspx#:~:text=Beginning%20in%20the%201990s%2C%20providers,overdose%20deaths%20increased%20as%20well>.
- 400
- 401
- 402 [3] Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of OxyContin® and
- 403 other opioid analgesics in the United States: 2002-2004. *The Journal of Pain*.
- 404 2005;6(10):662–672.
- 405 [4] Substance Abuse and Mental Health Services Administration. Substance Abuse
- 406 and Mental Health Services Administration, editor.: Risk and Protective Factors
- 407 and Initiation of Substance Use: Results from the 2014 National Survey on Drug
- 408 Use and Health. Substance Abuse and Mental Health Services Administration.
- 409 Accessed 11/05/24. <https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf>.
- 410
- 411 [5] Substance Abuse and Mental Health Services Administration. Substance Abuse
- 412 and Mental Health Services Administration, editor.: Key Substance Use and Men-
- 413 tal Health Indicators in the United States: Results from the 2016 National Survey
- 414 on Drug Use and Health. Substance Abuse and Mental Health Services Adminis-
- 415 tration. Accessed 12/12/23, [https://www.samhsa.gov/data/report/key-substan-](https://www.samhsa.gov/data/report/key-substance-use-and-mental-health-indicators-united-states-results-2016-national-survey)
- 416 [ce-use-and-mental-health-indicators-united-states-results-2016-national-survey](https://www.samhsa.gov/data/report/key-substance-use-and-mental-health-indicators-united-states-results-2016-national-survey).
- 417 [6] National Institute on Drug Abuse. National Institute on Drug Abuse, editor.:
- 418 Drug Overdose Deaths: Facts and Figures. National Institute on Drug Abuse.
- 419 Accessed 11/05/24, [https://nida.nih.gov/research-topics/trends-statistics/over-](https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates)
- 420 [dose-death-rates](https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates).
- 421 [7] of Health UD, Services H, et al.. of Health UD, Services H, et al., editors.: HHS
- 422 takes strong steps to address opioid-drug related overdose, death and dependence.
- 423 Washington, DC: Department of Health and Human Services.

- 424 [8] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for
425 chronic pain—United States, 2016. *Jama*. 2016;315(15):1624–1645.
- 426 [9] Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of
427 OxyContin. *New England Journal of Medicine*. 2012;367(2):187–189.
- 428 [10] Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid
429 abuse epidemic in the United States: lessons learned from OxyContin. *JAMA*
430 *psychiatry*. 2015;72(5):424–430.
- 431 [11] Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the
432 United States: a retrospective analysis of the past 50 years. *JAMA psychiatry*.
433 2014;71(7):821–826.
- 434 [12] Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, et al.
435 Increases in heroin overdose deaths—28 states, 2010 to 2012. *MMWR Morb*
436 *Mortal Wkly Rep*. 2014;63(39):849–854.
- 437 [13] Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls.
438 *Drug and alcohol dependence*. 2017;171:107–116.
- 439 [14] Spencer MR, Garnett M, Miniño AM. Drug overdose deaths in the United States,
440 2002-2022. US Department of Health and Human Services, Centers for Disease
441 Control and . . . ; 2024.
- 442 [15] National Institute on Drug Abuse. National Institute on Drug Abuse, editor.:
443 Substance Use and Military Life DrugFacts. National Institute on Drug Abuse.
444 Accessed 01/07/2025, [https://nida.nih.gov/publications/drugfacts/substance-u](https://nida.nih.gov/publications/drugfacts/substance-use-military-life#ref)
445 [se-military-life#ref](https://nida.nih.gov/publications/drugfacts/substance-use-military-life#ref).

- 446 [16] Lewis B, Hoffman L, Garcia CC, Nixon SJ. Race and socioeconomic status in
447 substance use progression and treatment entry. *Journal of ethnicity in substance*
448 *abuse*. 2018;17(2):150–166.
- 449 [17] U S Department of Health and Human Services. U S Department of Health
450 and Human Services, editor.: *Overdose Prevention Stratgey*. U.S. Department of
451 Health and Human Services. Accessed 01/07/2025, [https://www.hhs.gov/over](https://www.hhs.gov/overdose-prevention/)
452 [dose-prevention/](https://www.hhs.gov/overdose-prevention/).
- 453 [18] Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al.
454 Release from prison—a high risk of death for former inmates. *New England*
455 *Journal of Medicine*. 2007;356(2):157–165.
- 456 [19] Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al.
457 Receipt of timely addiction treatment and association of early medication treat-
458 ment with retention in care among youths with opioid use disorder. *JAMA*
459 *pediatrics*. 2018;172(11):1029–1037.
- 460 [20] Altekruise SF, Cosgrove CM, Altekruise WC, Jenkins RA, Blanco C. Socioeco-
461 nomic risk factors for fatal opioid overdoses in the United States: Findings from
462 the Mortality Disparities in American Communities Study (MDAC). *PloS one*.
463 2020;15(1):e0227966.
- 464 [21] Lin LA, Bohnert AS, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact
465 of the Opioid Safety Initiative on opioid-related prescribing in veterans. *Pain*.
466 2017;158(5):833–839.
- 467 [22] Department of Defense. Department of Defense, editor.: *Tricare; Mental health*
468 *and substance use disorder treatment*. Department of Defense. Accessed
469 01/07/2025, <https://www.govinfo.gov/content/pkg/FR-2016-09-02/pdf/2016-2>

- 470 [1125.pdf](#). Federal Register, Volume 81, Issue 171.
- 471 [23] Appalachian Regional Commission. Appalachian Regional Commission, editor.:
 472 Health Disparities Related to Opioid Misuse in Appalachia. Appalachian Regional
 473 Commission. Accessed 01/07/2025, [https://www.arc.gov/wp-content/uploads/2](https://www.arc.gov/wp-content/uploads/2020/06/HealthDisparitiesRelatedtoOpioidMisuseinAppalachiaApr2019.pdf)
 474 [020/06/HealthDisparitiesRelatedtoOpioidMisuseinAppalachiaApr2019.pdf](https://www.arc.gov/wp-content/uploads/2020/06/HealthDisparitiesRelatedtoOpioidMisuseinAppalachiaApr2019.pdf).
- 475 [24] Moody LN, Satterwhite E, Bickel WK. Substance use in rural Central Appalachia:
 476 Current status and treatment considerations. *Journal of Rural Mental Health*.
 477 2017;41(2):123.
- 478 [25] White E, Comiskey C. Heroin epidemics, treatment and ODE modelling.
 479 *Mathematical biosciences*. 2007;208(1):312–324.
- 480 [26] Liu J, Zhang T. Global behaviour of a heroin epidemic model with distributed
 481 delays. *Applied Mathematics Letters*. 2011;24(10):1685–1692.
- 482 [27] Fang B, Li XZ, Martcheva M, Cai LM. Global asymptotic properties of a
 483 heroin epidemic model with treat-age. *Applied Mathematics and Computation*.
 484 2015;263:315–331.
- 485 [28] Fang B, Li X, Martcheva M, Cai L. Global stability for a heroin model
 486 with age-dependent susceptibility. *Journal of Systems Science and Complexity*.
 487 2015;28(6):1243–1257.
- 488 [29] Ma M, Liu S, Li J. Bifurcation of a heroin model with nonlinear incidence rate.
 489 *Nonlinear Dynamics*. 2017;88:555–565.
- 490 [30] Wangari IM, Stone L. Analysis of a heroin epidemic model with saturated
 491 treatment function. *Journal of Applied Mathematics*. 2017;2017(1):1953036.

- 492 [31] Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, et al.
493 Prevention of prescription opioid misuse and projected overdose deaths in the
494 United States. *JAMA network open*. 2019;2(2):e187621–e187621.
- 495 [32] Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of
496 public policy responses to the US opioid epidemic. *American journal of public*
497 *health*. 2018;108(10):1394–1400.
- 498 [33] Fang B, Li X, Martcheva M, Cai L. GLOBAL STABILITY FOR A HEROIN
499 MODEL WITH TWO DISTRIBUTED DELAYS. *Discrete & Continuous*
500 *Dynamical Systems-Series B*. 2014;19(3).
- 501 [34] Kundu S, Kumari N, Kouachi S, Kundu P. Stability and bifurcation analysis of a
502 heroin model with diffusion, delay and nonlinear incidence rate. *Modeling Earth*
503 *Systems and Environment*. 2022;p. 1–12.
- 504 [35] Samanta G. Dynamic behaviour for a nonautonomous heroin epidemic model with
505 time delay. *Journal of Applied Mathematics and Computing*. 2011;35:161–178.
- 506 [36] Bentout S, Djilali S, Ghanbari B. Backward, Hopf bifurcation in a heroin epi-
507 demic model with treat age. *International Journal of Modeling, Simulation, and*
508 *Scientific Computing*. 2021;12(02):2150018.
- 509 [37] Bentout S, Kumar S, Djilali S. Hopf bifurcation analysis in an age-structured
510 heroin model. *The European Physical Journal Plus*. 2021;136(2):1–13.
- 511 [38] Djilali S, Touaoula TM, Miri SEH. A heroin epidemic model: very general non
512 linear incidence, treat-age, and global stability. *Acta Applicandae Mathematicae*.
513 2017;152:171–194.

- 514 [39] Duan XC, Li XZ, Martcheva M. Dynamics of an age-structured heroin transmis-
515 sion model with vaccination and treatment. *Math Biosci Eng.* 2019;16:397–420.
- 516 [40] Khan A, Zaman G, Ullah R, Naveed N. Optimal control strategies for a heroin
517 epidemic model with age-dependent susceptibility and recovery-age. *AIMS Math.*
518 2021;6(2):1377–1394.
- 519 [41] Liu L, Liu X. Mathematical analysis for an age-structured heroin epidemic model.
520 *Acta Applicandae Mathematicae.* 2019;164(1):193–217.
- 521 [42] Butler C, Stechlinski P. Modeling Opioid Abuse: A Case Study of the Opioid
522 Crisis in New England. *Bulletin of Mathematical Biology.* 2023;85(6):45.
- 523 [43] Wei F, Jiang H, Zhu Q. Dynamical behaviors of a heroin population model
524 with standard incidence rates between distinct patches. *Journal of the Franklin*
525 *Institute.* 2021;358(9):4994–5013.
- 526 [44] Wang J, Sun H. Analysis of a diffusive heroin epidemic model in a heterogeneous
527 environment. *Complexity.* 2020;2020(1):8268950.
- 528 [45] Zhang L, Xing Y. Stability Analysis of a Reaction-Diffusion Heroin Epidemic
529 Model. *Complexity.* 2020;2020(1):3781425.
- 530 [46] Phillips T, Lenhart S, Strickland WC. A data-driven mathematical model of the
531 heroin and fentanyl epidemic in Tennessee. *Bulletin of Mathematical Biology.*
532 2021;83(10):97.
- 533 [47] Battista NA, Percy LB, Strickland WC. Modeling the prescription opioid
534 epidemic. *Bulletin of mathematical biology.* 2019;81:2258–2289.
- 535 [48] Deas A, Spannaus A, Fernando H, Hanson HA, Kapadia AJ, Trafton J, et al.
536 Identifying spatiotemporal patterns in opioid vulnerability: investigating the links

537 between disability, prescription opioids and opioid-related mortality. BMC Public
538 Health. 2025;25(1):1759.

539 [49] National Survey on Drug Use and Health. National Survey on Drug Use and
540 Health, editor.: State Data Tables and Reports From the 2019-2020 NSDUH.
541 National Survey on Drug Use and Health. Accessed 12/13/24, [https://www.sa
542 mhsa.gov/data/nsduh/state-reports-NSDUH-2020](https://www.samhsa.gov/data/nsduh/state-reports-NSDUH-2020).

543 [50] American Psychological Association. American Psychological Association, editor.:
544 APA Dictionary of Psychology. American Psychological Association. Accessed
545 12/18/23, <https://dictionary.apa.org/substance-use-disorder>.

546 [51] Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient
547 treatment of opiate dependence. Ir Med J. 2010;103(6):176–9.

548 [52] Reed PM, Hadjimichael A, Malek K, Karimi T, Vernon CR, Srikrishnan V, et al.
549 Addressing uncertainty in multisector dynamics research. Zenodo. 2022;.

550 [53] Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH,
551 et al. Medication-assisted treatment with methadone: assessing the evidence.
552 Psychiatric services. 2014;65(2):146–157.

553 [54] Food and Drug Administration. Food and Drug Administration, editor.: Access
554 to Naloxone Can Save a Life During an Opioid Overdose. Food and Drug Admin-
555 istration. Accessed 12/18/24, [https://www.fda.gov/consumers/consumer-updat
556 es/access-naloxone-can-save-life-during-opioid-overdose](https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose).

557 [55] Centers for Disease Control and Prevention. Centers for Disease Control and
558 Prevention, editor.: Overdose Prevention: Fentanyl. Centers for Disease Control
559 and Prevention. Accessed 11/08/24, [https://www.cdc.gov/overdose-prevention/
560 about/fentanyl.html](https://www.cdc.gov/overdose-prevention/about/fentanyl.html).

- 561 [56] Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzo-
562 diazepam prescriptions and overdose mortality in the United States, 1996–2013.
563 American journal of public health. 2016;106(4):686–688.
- 564 [57] Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association
565 between concurrent use of prescription opioids and benzodiazepines and overdose:
566 retrospective analysis. *bmj*. 2017;356.

567 **Declarations**

568 **Ethics approval and consent to participate**

569 Not applicable.

570 **Consent for publication**

571 Not applicable.

572 **Availability of data and materials**

573 All data analyzed during this study are included in its supplementary materials. The
574 code used in this study is publicly available at [https://github.com/keversma/Opioid](https://github.com/keversma/Opioid_Model_Knoxville_TN)
575 [_Model_Knoxville_TN](https://github.com/keversma/Opioid_Model_Knoxville_TN).

576 **Competing interests**

577 The authors declare that they have no competing interests.

578 **Funding**

579 This quality improvement initiative is sponsored by the U.S. Department of Veterans
580 Affairs (VA), is supported by and utilizes VA-funded resources from the Knowledge

581 Discovery Infrastructure (KDI) at Oak Ridge National Laboratory and is backed by
582 the Department of Energy (DOE) Office of Science. The manuscript has been authored
583 by UT-Battelle LLC under contract DE-AC05-00OR22725 with the DOE. The US
584 government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish
585 or reproduce this manuscript or allow others to do so for US government purposes.
586 DOE will provide public access to these results in accordance with the DOE Public
587 Access Plan (<http://energy.gov/downloads/doe-public-access-plan>).

588 The initiative aimed to improve care for Veterans within the Veterans Health
589 Administration (VHA) and involved models specifically tailored to the VHA system.
590 Therefore, it is not generalizable outside of VHA and is officially considered non-
591 research by the VHA. Oak Ridge National Laboratory received Institutional Review
592 Board (IRB) approval due to the secondary use of patient data, which complies with
593 internal policies and standards. The authors acknowledge the broader partnership and
594 express gratitude to the Veterans receiving care at VA.

595 Dissemination of this work at conferences was supported by the Simons Foundation
596 Collaboration Grants for Mathematicians.

597 **Authors' contributions**

598 KE designed the model, built the computational framework, and performed all simu-
599 lations, analysis, and data visualization under the advisement of WCS with valuable
600 input from AS. RC and LBP assisted in development. AK and JT provided the sup-
601 port necessary to carry out the work. KE drafted the manuscript, and all the authors
602 provided crucial input on several iterations of the manuscript. All authors read and
603 approved the final version of the manuscript.

604 **Acknowledgements**

605 Not applicable.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [EversmanOpioidSuppMaterial.pdf](#)